DENVER — Treatment of radioactive iodine–resistant metastatic differentiated thyroid carcinoma (RMDTC) with lenvatinib (Lenvima, Eisai) in the real-world setting shows consistently encouraging ...

2.3 The list price of lenvatinib is £1,437.00 per 30‑capsule pack (4 mg and 10 mg). The list price of everolimus is £2,250.00 per 30‑tablet pack of 5 mg everolimus. The company has agreed a patient ...

In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus ...

WOODCLIFF LAKE, N.J., Sept. 24, 2019 /PRNewswire/ -- Eisai today announced the presentation of new data and analyses via one oral proffered paper presentation, four poster discussions and seven ...

Among patients receiving lenvatinib plus pembrolizumab, the median dose intensity of lenvatinib was 13.8 mg per day, and the median number of cycles of pembrolizumab was 10.

This is a disease where we have to individualize the therapy for each and every patient. That’s not just the treatment choices that we make in terms of drugs, surgery, and radioactive iodine, but also ...

WOODCLIFF LAKE, N.J., Aug. 11, 2020 /PRNewswire/ -- Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the ...

Eisai announced that the Food and Drug Administration (FDA) granted lenvatinib Breakthrough Therapy designation for use in patients with advanced or metastatic renal cell carcinoma (RCC) who were ...

Lenvatinib was administered orally at a dose of 24 mg per day in 28-day cycles. Dose adherence was monitored by pill diaries. Treatment was continued until disease progression, death, unacceptable ...

In part 1 of LEAP-015 (Lead-in Phase), an initial cohort received induction with lenvatinib 8 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks (×2) and investigator’s ...